Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: Identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity

Modern Pathology

Volumn 19, Issue 4, 2006, Pages 514-523

  Yaziji, Hadi ^a   Battifora, Hector ^b   Barry, Todd S ^c   Hwang, Harry C ^c   Bacchi, Carlos E ^d   McIntosh, Martin W ^e   Kussick, Steven J ^c   Gown, Allen M ^c  

^a Ancillary Pathways   (United States)

^b Pathology Consultation Services   (United States)

^c PHENOPATH LABORATORIES   (United States)

^d Fred Hutchinson Cancer Research Center ^*  (Brazil)

^e Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Asbestos; Calretinin; Immunohistochemistry; Logic regression; Mesothelioma; Pleura

Indexed keywords

BLOOD GROUP ANTIGEN; CALRETININ; CYTOKERATIN 5; GENE PRODUCT; MESOTHELIN; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; THROMBOMODULIN; VIMENTIN;

ARTICLE; BREAST CARCINOMA; DIAGNOSTIC ACCURACY; EPITHELIOID CELL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOGISTIC REGRESSION ANALYSIS; LUNG ADENOCARCINOMA; MESOTHELIOMA; NEPHROBLASTOMA; OVARY CARCINOMA; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STOMACH CARCINOMA; ULTRASTRUCTURE;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; BREAST NEOPLASMS; CALCIUM-BINDING PROTEIN, VITAMIN D-DEPENDENT; CARCINOEMBRYONIC ANTIGEN; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-5; KERATINS; LUNG NEOPLASMS; MEMBRANE GLYCOPROTEINS; MESOTHELIOMA; MULTIVARIATE ANALYSIS; OVARIAN NEOPLASMS; SENSITIVITY AND SPECIFICITY; STOMACH NEOPLASMS; THROMBOMODULIN; TUMOR MARKERS, BIOLOGICAL; WT1 PROTEINS;

EID: 33645275721     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800534     Document Type: Article

References (78)

1. Leong AS, Stevens MW, Mukherjee TM. Malignant mesothelioma: cytologic diagnosis with histologic, immunohistochemical, and ultrastructural correlation. Semin Diagn Pathol 1992;9:141-150.
2. Di Muzio M, Spoletini L, Strizzi L, et al. Prognostic significance of presence and reduplication of basal lamina in malignant pleural mesothelioma. Hum Pathol 2000;31:1341-1345.
3. Doglioni C, Tos AP, Laurino L, et al. Calretinin: a novel immunocytochemical marker for mesothelioma. Am J Surg Pathol 1996;20:1037-1046.
4. Ordonez NG. Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma. Mod Pathol 1998;11:929-933.
5. Amin KM, Litzky LA, Smythe WR, et al. Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma. Am J Pathol 1995;146:344-356.
6. Kumar-Singh S, Segers K, Rodeck U, et al. WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis. J Pathol 1997;181:67-74.
7. Chang K, Pai LH, Pass H, et al. Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma. Am J Surg Pathol 1992;16:259-268.
8. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA 1996;93:136-140.
9. Clover J, Oates J, Edwards C. Anti-cytokeratin 5/6: a positive marker for epithelioid mesothelioma. Histopathology 1997;31:140-143.
10. Ordonez N. Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma. Am J Surg Pathol 1998;22:1215-1221.
11. Riera JR, Astengo-Osuna C, Longmate JA, et al. The immunohistochemical diagnostic panel for epithelial mesothelioma: a reevaluation after heat-induced epitope retrieval [see comments]. Am J Surg Pathol 1997;21:1409-1419.
12. Ordonez NG. The value of antibodies 44-3A6, SM3, HBME-1, and thrombomodulin in differentiating epithelial pleural mesothelioma from lung adenocarcinoma: a comparative study with other commonly used antibodies. Am J Surg Pathol 1997;21:1399-1408.
13. Collins CL, Ordonez NG, Schaefer R, et al. Thrombomodulin expression in malignant pleural mesothelioma and pulmonary adenocarcinoma. Am J Pathol 1992;141:827-833.
14. Andressen C, Blumcke I, Celio MR. Calcium-binding proteins: selective markers of nerve cells. Cell Tissue Res 1993;271:181-208.
15. Walker C, Rutten F, Yuan X, et al. Wilms' tumor suppressor gene expression in rat and human mesothelioma. Cancer Res 1994;54:3101-3106.
16. Hecht JL, Lee BH, Pinkus JL, et al. The value of Wilms tumor susceptibility gene 1 in cytologic preparations as a marker for malignant mesothelioma. Cancer 2002;96:105-109.
17. Oates J, Edwards C. HBME-1, MOC-31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma. Histopathology 2000;36:341-347.
18. Ordonez NG. Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma. Am J Surg Pathol 2000;24:598-606.
19. Nagle RB, Bocker W, Davis JR, et al. Characterization of breast carcinomas by two monoclonal antibodies distinguishing myoepithelial from luminal epithelial cells. J Histochem Cytochem 1986;34:869-881.
20. Cury PM, Butcher DN, Fisher C, et al. Value of the mesothelium-associated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura. Mod Pathol 2000;13:107-112.
21. Chu PG, Weiss LM. Expression of cytokeratin 5/6 in epithelial neoplasms: an immunohistochemical study of 509 cases. Mod Pathol 2002;15:6-10.
22. Attanoos RL, Webb R, Dojcinov SD, et al. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum. Histopathology 2002;40:237-244.
23. Moll R, Dhouailly D, Sun TT. Expression of keratin 5 as a distinctive feature of epithelial and biphasic mesotheliomas. An immunohistochemical study using monoclonal antibody AE14. Virchows Arch B Cell Pathol Incl Mol Pathol 1989;58:129-145.
24. Kaufmann O, Fietze E, Mengs J, et al. Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Am J Clin Pathol 2001;116:823-830.
25. Chang K, Pastan I, Willingham MC. Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer 1992;50:373-381.
26. Chang K, Pai LH, Batra JK, et al. Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium. Cancer Res 1992;52:181-186.
27. Argani P, Iacobuzio-Donahue C, Ryu B, et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 2001;7:3862-3868.
28. Battifora H, Kopinski MI. Distinction of mesothelioma from adenocarcinoma. An immunohistochemical approach. Cancer 1985;55:1679-1685.
29. Wirth PR, Legier J, Wright Jr GL. Immunohistochemical evaluation of seven monoclonal antibodies for differentiation of pleural mesothelioma from lung adenocarcinoma. Cancer 1991;67:655-662.
30. Sheibani K, Battifora H, Burke JS. Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu M1 antigen. Am J Pathol 1986;123:212-219.
31. Sheibani K, Battifora H, Burke JS, et al. Leu-M1 antigen in human neoplasms. An immunohistologic study of 400 cases. Am J Surg Pathol 1986;10:227-236.
32. Ordonez NG. The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma. Am J Surg Pathol 1989;13:276-291.
33. Wick MR, Loy T, Mills SE, et al. Malignant epithelioid pleural mesothelioma versus peripheral pulmonary adenocarcinoma: a histochemical, ultrastructural, and immunohistologic study of 103 cases. Hum Pathol 1990;21:759-766.
34. Gaffey MJ, Mills SE, Swanson PE, et al. Immunoreactivity for BER-EP4 in adenocarcinomas, adenomatoid tumors, and malignant mesotheliomas. Am J Surg Pathol 1992;16:593-599.
35. Ordonez NG. Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The MD Anderson experience and a critical review of the literature. Am J Clin Pathol 1998;109:85-89.
36. Ordonez NG. Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma. Hum Pathol 1998;29:166-169.
37. McIntosh MW, Pepe MS. Combining several screening tests: optimality of the risk score. Biometrics 2002;58:657-664.
38. Smekal G, Scharl A, von Duvillard SP, et al. Accuracy of neuro-fuzzy logic and regression calculations in determining maximal lactate steady-state power output from incremental tests in humans. Eur J Appl Physiol 2002;88:264-274.
39. Kooperberg C, Ruczinski I. Identifying interacting SNPs using Monte Carlo logic regression. Genet Epidemiol 2005;28:157-170.
40. Kooperberg C, Ruczinski I, LeBlanc ML, et al. Sequence analysis using logic regression. Genet Epidemiol 2001;21(Suppl 1):S626-S631.
41. Keles S, van der Laan MJ, Vulpe C. Regulatory motif finding by logic regression. Bioinformatics 2004;20:2799-2811.
42. Janes H, Pepe M, Kooperberg C, et al. Identifying target populations for screening or not screening using logic regression. Stat Med 2005;24:1321-1338.
43. Etzioni R, Falcon S, Gann PH, et al. Prostate-specific antigen and free prostate-specific antigen in the early detection of prostate cancer: do combination tests improve detection? Cancer Epidemiol Biomarkers Prev 2004;13:1640-1645.
44. Feng Q, Balasubramanian A, Hawes SE, et al. Detection of hypermethylated genes in women with and without cervical neoplasia. J Natl Cancer Inst 2005;97:273-282.
45. Falconieri G, Bussani R, Mirra M, et al. Pseudomesotheliomatous angiosarcoma: a pleuropulmonary lesion simulating malignant pleural mesothelioma. Histopathology 1997;30:419-424.
46. Ordonez NG. The immunohistochemical diagnosis of epithelial mesothelioma. Hum Pathol 1999;30:313-323.
47. Ordonez NG. In search of a positive immunohistochemical marker for mesothelioma: an update. Adv Anat Pathol 1998;5:53-60.
48. Moran CA, Wick MR, Suster S. The role of immunohistochemistry in the diagnosis of malignant mesothelioma. Semin Diagn Pathol 2000;17:178-183.
49. Sheibani K. Immunopathology of malignant mesothelioma. Hum Pathol 1994;25:219-220.
50. Leong AS, Vernon-Roberts E. The immunohistochemistry of malignant mesothelioma. Pathol Annu 1994;29(Part 2):157-179.
51. Bedrossian CW, Bonsib S, Moran C. Differential diagnosis between mesothelioma and adenocarcinoma: a multimodal approach based on ultrastructure and immunocytochemistry. Semin Diagn Pathol 1992;9:124-140.
52. Sheibani K, Esteban JM, Bailey A, et al. Immunopathologic and molecular studies as an aid to the diagnosis of malignant mesothelioma. Hum Pathol 1992;23:107-116.
53. Otis CN, Carter D, Cole S, et al. Immunohistochemical evaluation of pleural mesothelioma and pulmonary adenocarcinoma. A bi-institutional study of 47 cases. Am J Surg Pathol 1987;11:445-456.
54. Corson JM, Pinkus GS. Mesothelioma: profile of keratin proteins and carcinoembryonic antigen: an immunoperoxidase study of 20 cases and comparison with pulmonary adenocarcinomas. Am J Pathol 1982;108:80-87.
55. Churg A. Immunohistochemical staining for vimentin and keratin in malignant mesothelioma. Am J Surg Pathol 1985;9:360-365.
56. Sosolik RC, McGaughy VR, De Young BR. Anti-MOC-31: a potential addition to the pulmonary adenocarcinoma versus mesothelioma immunohistochemistry panel. Mod Pathol 1997;10:716-719.
57. Leers MP, Aarts MM, Theunissen PH. E-cadherin and calretinin: a useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma. Histopathology 1998;32:209-216.
58. Brockstedt U, Gulyas M, Dobra K, et al. An optimized battery of eight antibodies that can distinguish most cases of epithelial mesothelioma from adenocarcinoma. Am J Clin Pathol 2000;114:203-209.
59. Carella R, Deleonardi G, D'Errico A, et al. Immunohistochemical panels for differentiating epithelial malignant mesothelioma from lung adenocarcinoma: a study with logistic regression analysis. Am J Surg Pathol 2001;25:43-50.
60. Betta PG. The role of immunohistochemistry in the diagnosis of malignant mesothelioma. Monaldi Arch Chest Dis 1998;53:186-187.
61. Dejmek A, Hjerpe A. Reactivity of six antibodies in effusions of mesothelioma, adenocarcinoma and mesotheliosis: stepwise logistic regression analysis. Cytopathology 2000;11:8-17.
62. Chenard-Neu MP, Kabou A, Mechine A, et al. Immunohistochemistry in the differential diagnosis of mesothelioma and adenocarcinoma. Evaluation of 5 new antibodies and 6 traditional antibodies. Ann Pathol 1998;18:460-465.
63. Roberts F, Harper CM, Downie I, et al. Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies. Am J Clin Pathol 2001;116:253-262.
64. Osborn M, Pelling N, Walker MM, et al. The value of 'mesothelium- associated' antibodies in distinguishing between metastatic renal cell carcinomas and mesotheliomas. Histopathology 2002;41:301-307.
65. Abutaily AS, Addis BJ, Roche WR. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies. J Clin Pathol 2002;55:662-668.
66. Wick MR, Moran CA, Mills SE, et al. Immunohistochemical differential diagnosis of pleural effusions, with emphasis on malignant mesothelioma. Curr Opin Pulm Med 2001;7:187-192.
67. Ordonez NG. Role of immunohistochemistry in differentiating epithelial mesothelioma from adenocarcinoma. Review and update. Am J Clin Pathol 1999;112:75-89.
68. Comin CE, Novell! L, Boddi V, et al. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma. Hum Pathol 2001;32:529-536.
69. Peralta S-A, Knudsen KA, Jaurand MC, et al. The differential expression of N-cadherin and E-cadherin distinguishes pleural mesotheliomas from lung adenocarcinomas [see comments]. Hum Pathol 1995;26:1363-1369.
70. Kitazume H, Kitamura K, Mukai K, et al. Cytologic differential diagnosis among reactive mesothelial cells, malignant mesothelioma, and adenocarcinoma: utility of combined E-cadherin and calretinin immunostaining. Cancer 2000;90:55-60.
71. Ordonez NG. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol 2003;27:1031-1051.
72. Ordonez NG. Value of E-cadherin and N-cadherin immunostaining in the diagnosis of mesothelioma. Hum Pathol 2003;34:749-755.
73. Trupiano JK, Geisinger KR, Willingham MC, et al. Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers. Mod Pathol 2004;17:476-481.
74. Esteban JM, Battifora H. Tumor immunophenotype: comparison between primary neoplasm and its meta-stases. Mod Pathol 1990;3:192-197.
75. Ordonez NG. The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study. Hum Pathol 2004;35:697-710.
76. Chu AY, Litzky LA, Pasha TL, et al. Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Mod Pathol 2005;18:105-110.
77. Kimura N, Kimura I. Podoplanin as a marker for mesothelioma. Pathol Int 2005;55:83-86.
78. Ordonez NG. D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma. Hum Pathol 2005;36:372-380.